急性冠脉综合征药物干预策略经济学评析综述

• 药物经济学 • 上一篇

急性冠脉综合征药物干预策略经济学评析综述

陈平钰,马爱霞

中国药科大学国际医药商学院,中国药科大学国际医药商学院

收稿日期:2014-04-07 修回日期:2014-05-25 出版日期:2014-06-25 发布日期:2014-06-25

Pharmacoeconomics Analysis on Pharmacotherapy of Acute Coronary Syndromes

马爱霞

School of International Pharmaceutical Business，China Pharmaceutical University,School of International Pharmaceutical Business，China Pharmaceutical University

Received:2014-04-07 Revised:2014-05-25 Online:2014-06-25 Published:2014-06-25

摘要/Abstract

摘要： 通过查阅国内外相关文献，对急性冠脉综合征药物干预策略进行综合评析，综述急性冠脉综合征药物干预策略的药物经济学评价结果，得出具有成本-效果优势的药物干预策略，但仍需进一步深入研究。

陈平钰,马爱霞. 急性冠脉综合征药物干预策略经济学评析综述[J]. .

马爱霞. Pharmacoeconomics Analysis on Pharmacotherapy of Acute Coronary Syndromes[J]. .

[1]世界卫生组织官方网站http://www.who.int/zh/
[2]中国卫生统计年鉴,2012
[3]陶寿淇,武阳丰. 医疗卫生人员心血管病防治知识[M].中囯友谊出版公司,2000.
[4]胡善联.药物经济学[M]. 高等教育出版社,2009.
[5] David H. Fitchett, Pierre Theroux, James M. Brophy et al. Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST–Segment Elevation ACS [J]. Canadian Journal of Cardiology, 2011(27): S387–S401.
[6]Crespin D J, Federspiel J J, Biddle A K, et al. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis[J]. Value in Health, 2011, 14(4): 483-491.
[7]沈卫峰. 《急性ST段抬高型心肌梗死诊断和治疗指南》解读[J]. 国际心血管病杂志,2010,37(6):321-323.
[8]王丽君. 非ST段抬高急性冠脉综合征治疗策略(综述)[J]. 中国城乡企业卫生,2013(2):63-65.
[9]中华医学会心血管病学分会. 对病情稳定的NSTE-ACS患者进行二级预防至关重要——非ST段抬高急性冠状动脉综合征诊断和治疗指南(2012版)[J]. 中国社区医师,2012(26):7-8.
[10]Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials [J]. Lancet, 2009 37(3):1849-1860.
[11]白婧,杨庭树. 急性冠脉综合征新型抗栓药物的研究进展[J]. 军医进修学院学报,2012,33(1):95-97.
[12]Lindgren P, J?nsson B, Yusuf S. Cost‐effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long‐term model based on the cure trial [J]. Journal of internal medicine, 2004, 255(5): 562-570.
[13]James S, ?kerblom A, Cannon C P, et al. Comparison of ticagrelor, the first reversible oral P2Y< sub> 12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial[J]. American heart journal, 2009, 157(4): 599-605.
[14]王婧,袁晋青. 氯吡格雷抵抗的临床处理[J]. 心血管病学进展,2012,33(1):24-27.
[15] 齐欣. 急性冠脉综合征抗血小板治疗的循证医学[J]. 临床药物治疗杂志,2012,10(5):8-12.
[16] Craig I. Coleman, Brendan L. Limone. Cost-Effectiveness of Universal and Platelet Reactivity Assay-Driven Antiplatelet Therapy in Acute Coronary Syndrome. Am J Cardiol, 2013, 112:355-362.
[17] Jaime Latour-P?rez, Eva de Miguel Balsa, Lourdes Beteg?n et al. Using Triple Antiplatelet Therapy in Patients with Non-ST Elevation Acute Coronary Syndrome Managed Invasively: A Cost-Effectiveness Analysis. Value in Health, 2008,11(5):853-861.
[18] Glaser R, Glick H A, Herrmann H C, et al. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromesa cost-effectiveness analysis [J]. Journal of the American College of Cardiology, 2006, 47(3): 529-537.
[19] Schwenkglenks M, Brazier J E, Szucs T D, et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non–ST-segment elevation acute coronary syndromes[J]. Value in Health, 2011, 14(1): 24-33.
[20] Sculpher M J, Lozano-Ortega G, Sambrook J, et al. Fondaparinux versus Enoxaparin in non–ST-elevation acute coronary syndromes: Short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial[J]. American heart journal, 2009, 157(5): 845-852.
[21] 何江江,张崖冰,高润霖,申立军,克拉斯.里克纳,李黎,胡善联. 替格瑞洛与氯吡格雷治疗急性冠脉综合征的药物经济学分析[J]. 中国药物经济学,2013(3):27-32.
[22] 夏亚飞,阎姝. 国产与进口氯吡格雷治疗急性冠脉综合征的成本-效果分析[J]. 中国药房,2012,23(40):3801-3803.
[23] 杨美君,张邦升. 两种方案治疗急性冠脉综合征的成本-效果分析[J]. 宁夏医学杂志,2010,32(12):1252-1253.
[24] 毛静远,毕颖斐,王恒和,王贤良,张伯礼. 中西医结合单元疗法治疗急性冠脉综合征的成本效果分析[J]. 上海中医药杂志,2009,43(11):29-32.